Form 4: Director Nancy Wysenski Increases Stake in Cytokinetics

Director Nancy Wysenski acquired 95 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Summary

• Director Nancy Wysenski acquired 95 shares of Cytokinetics (CYTK) common stock on April 15, 2026.
• The shares were acquired at a price of $65.37 per share.
• The acquisition was made via the Director Equity in Lieu of Cash Retainer Program.
• Following this transaction, the director's total beneficial ownership is 31,066 shares.
• The acquired shares are fully vested.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing reflecting standard director compensation practices.

Positives

• Director demonstrates alignment with shareholder interests by opting for equity compensation in lieu of cash.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine Form 4 insider transaction filing.

Industry Context

StockSavvy.ai notes that director participation in equity-in-lieu-of-cash programs is a standard corporate governance practice, signaling confidence in the company's long-term trajectory without necessarily indicating a major strategic shift.

Comparison to Industry Standards

• The use of equity-in-lieu-of-cash retainers is a common practice among mid-cap and large-cap biotechnology firms to preserve cash reserves for R&D activities.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensation transaction.

Next Steps

• None.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Director Compensation, Equity Ownership